Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations.
暂无分享,去创建一个
S. Majumdar | James M. Hill | A. Mitra | K. Patel | D. Neumann | R. Jain | Y. Nashed | M. Itahashi | J. Hill
[1] E. Clercq,et al. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus , 1991, European Journal of Clinical Microbiology and Infectious Diseases.
[2] S. Majumdar,et al. Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. , 2004, Advanced drug delivery reviews.
[3] A. Osterhaus,et al. Human herpes simplex virus keratitis: the pathogenesis revisited , 2004, Ocular immunology and inflammation.
[4] J. Oosterhuis,et al. Aciclovir and Trifluorothymidine in herpetic keratitis preliminary report of a multicentered trial , 1981, Documenta Ophthalmologica.
[5] S. Majumdar,et al. Expression of Peptide Transporters on the Rabbit Retina: A Strategy to Improve Retinal Delivery of Ganciclovir , 2004 .
[6] A. Mitra,et al. Synthesis and characterization of novel dipeptide ester prodrugs of acyclovir. , 2003, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
[7] James M. Hill,et al. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. , 2003, Investigative ophthalmology & visual science.
[8] A. P. Ten Eick,et al. Stability of valganciclovir in extemporaneously compounded liquid formulations. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[9] Sridhar Duvvuri,et al. Drug delivery to the retina: challenges and opportunities , 2003, Expert opinion on biological therapy.
[10] A. Mitra,et al. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea , 2003, Current eye research.
[11] S. Majumdar,et al. Functional expression of a sodium dependent nucleoside transporter on rabbit cornea: Role in corneal permeation of acyclovir and idoxuridine , 2003, Current eye research.
[12] N. Anaizi,et al. Stability of valganciclovir in an extemporaneously compounded oral liquid. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[13] A. Mitra,et al. Effect of mono- and di-acylation on the ocular disposition of ganciclovir: physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs. , 2002, Journal of pharmaceutical sciences.
[14] P. Reusser. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts , 2001, Expert opinion on investigational drugs.
[15] M. Höglund,et al. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. , 2001, The Journal of antimicrobial chemotherapy.
[16] A. Guo,et al. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. , 1998, Biochemical and biophysical research communications.
[17] J. Neyts,et al. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells , 1998, Gene Therapy.
[18] S. Resnikoff,et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. , 1997, Cornea.
[19] S. Amasheh,et al. Transport of Charged Dipeptides by the Intestinal H+/Peptide Symporter PepT1 Expressed in Xenopus laevis Oocytes , 1997, The Journal of Membrane Biology.
[20] D. Easty,et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. , 1996, The British journal of ophthalmology.
[21] H. Serafinowska,et al. Synthesis and Properties of S-Phosphates of Some Antiviral Acyclonucleosides , 1994 .
[22] E. De Clercq,et al. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro. , 1991, The Journal of infectious diseases.
[23] G. Høvding. A comparison between acyclovir and trifluorothymidine ophthalmic ointment in the treatment of epithelial dendritic keratitis , 1989, Acta ophthalmologica.
[24] H. Lazarus,et al. An in vitro study of ophthalmic antiviral agent toxicity on rabbit corneal epithelium. , 1988, Antiviral research.
[25] D Edwards,et al. The efficiency of simulation-based multiple comparisons. , 1987, Biometrics.
[26] C. Foster,et al. Antiviral medications and corneal wound healing. , 1984, Antiviral research.
[27] D. Pavan-Langston,et al. Antiviral medication and corneal wound healing. , 1974, Archives of ophthalmology.
[28] H. Kaufman. Clinical Cure of Herpes Simplex Keratitis by 5-Iodo-2'-Deoxyuridine , 1962, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.